Blinatumomab Assigned Breakthrough Therapy Designation to Treat Acute Lymphoblastic Leukemia
Amgen has announced that the FDA has designated its drug, blinatumomab, Breakthrough Therapy status.
Diagnosis & Disease Information
Leukemia Treatment Could Involve Drugs That Block DNA Repair Defects
A drug originally designed for killing a limited type of cancer cells could potentially be used to treat leukaemia.
FDA Fast Tracks AG-221 to Treat AML
The FDA has granted Fast Track designation to AG-221, a first-in-classinhibitor, to treat AML.
Thiopurines Used to Treat IBD May Increase Risk of Leukemia
Thiopurines, a class of immunosuppressive agents widely used to treat irritable bowel disease (IBD) and rheumatoid arthritis, were found to increase the risk of myeloid disorders seven times.
FDA Approves Zydelig for Three Hematologic Cancers
The FDA has approved Zydelig for relapsed chronic lymphocytic leukemia, follicular B-cell non-Hodgkin lymphoma, and small lymphocytic lymphoma.
Arzerra Fails in Late-stage Trial
In a late-stage trial, Arzerra was not able to treat patients with bulky fludarabine-refractory chronic lymphocytic leukemia more effectively than other drugs.
STAT5 Inhibition Helps Kill Cancer Cells
When blocking STAT5 in conjunction with exposure to a regular anti-cancer treatment, leukemia cells were more effectively targeted.
Leukemia Cell Recognition Presents New Possibility for Therapy
A newly identified mode of cancer cell recognition by the immune system opens up new possibilities for leukemia immunotherapy.
‘Genetic Switch’ Normalizes Leukemia Cells
A new “genetic switch” technology may hold the key to “reversing” a common type of childhood leukemia, according to researchers from Melbourne.
Medication Adherence Low Among Child Leukemia Survivors
One in four child survivors of acute lymphocytic leukemia fail to regularly take maintenance medication to prevent disease recurrence.
- Loading...
Loading...
Next post in Hematologic Cancers
Loading... 
Loading...